Dermatomyositis associated with omalizumab therapy for severe asthma: a case report
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1710-1492
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Dermatomyositis associated with omalizumab therapy for severe asthma: a case report ; volume:15 ; number:1 ; day:17 ; month:1 ; year:2019 ; pages:1-5 ; date:12.2019
Allergy, asthma and clinical immunology ; 15, Heft 1 (17.1.2019), 1-5, 12.2019
- Urheber
-
Jeimy, Samira
Basharat, Pari
Lovegrove, Fiona
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13223-019-0319-4
- URN
-
urn:nbn:de:101:1-2019021822403094702732
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Jeimy, Samira
- Basharat, Pari
- Lovegrove, Fiona
- SpringerLink (Online service)
Ähnliche Objekte (12)
Severe asthma and the omalizumab option
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
Omalizumab in patients with severe asthma and persistent sputum eosinophilia
Omalizumab therapy in a 13-year-old boy with severe persistent asthma and concomitant eosinophilic esophagitis
Follicular T Helper and Breg Cell Balance in Severe Allergic Asthma Before and After Omalizumab Therapy
Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
Efficacy of Omalizumab therapy in a case of severe atopic dermatitis
Tailored therapy for severe asthma
Biological therapy for severe asthma
Omalizumab Transitions in Severe Asthma: Factors Influencing Switching Decisions and Timing for Optimal Response
Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study
Severe asthma and the omalizumab option
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
Omalizumab in patients with severe asthma and persistent sputum eosinophilia
Omalizumab therapy in a 13-year-old boy with severe persistent asthma and concomitant eosinophilic esophagitis
Follicular T Helper and Breg Cell Balance in Severe Allergic Asthma Before and After Omalizumab Therapy
Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
Efficacy of Omalizumab therapy in a case of severe atopic dermatitis
Tailored therapy for severe asthma
Biological therapy for severe asthma
Omalizumab Transitions in Severe Asthma: Factors Influencing Switching Decisions and Timing for Optimal Response
Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study
Severe asthma and the omalizumab option
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
Omalizumab in patients with severe asthma and persistent sputum eosinophilia
Omalizumab therapy in a 13-year-old boy with severe persistent asthma and concomitant eosinophilic esophagitis
Follicular T Helper and Breg Cell Balance in Severe Allergic Asthma Before and After Omalizumab Therapy
Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
Efficacy of Omalizumab therapy in a case of severe atopic dermatitis
Tailored therapy for severe asthma
Biological therapy for severe asthma
Omalizumab Transitions in Severe Asthma: Factors Influencing Switching Decisions and Timing for Optimal Response